Terms: = Ovarian cancer AND PPFIBP1, L2, 8496, ENSG00000110841, hSGT2, hSgt2p
89 results:
1. Review on Sertoli-Leydig Cell Tumours of the Ovary.
Muscat C; Calleja-Agius J
Discov Med; 2024 Feb; 36(181):234-247. PubMed ID: 38409829
[TBL] [Abstract] [Full Text] [Related]
2. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
[TBL] [Abstract] [Full Text] [Related]
3. Improving In Vivo Tumor Accumulation and Efficacy of Platinum Antitumor Agents by Electronic Tuning of the Kinetic Lability.
M M; Chhatar S; Gadre S; Paul S; Vaidya SP; Khatri S; Duari P; Kode J; Ingle A; Kolthur-Seetharam U; Patra M
Chemistry; 2024 Jan; 30(4):e202302720. PubMed ID: 37888749
[TBL] [Abstract] [Full Text] [Related]
4. Synthesis, characterization, and biological properties of novel Schiff bases containing pentafluorophenyl hydrazine.
Hamurcu F
J Biochem Mol Toxicol; 2023 Dec; 37(12):e23512. PubMed ID: 37638565
[TBL] [Abstract] [Full Text] [Related]
5. FOXL2 Mutation Status in Sex Cord-stromal Tumors Cannot be Predicted by Morphology.
Wessman S; Fuentes BB; Severin-Karlsson J; Westbom-Fremer S; Nistér M; Kokaraki G; Petta TB; Haglund F; Carlson JW
Int J Gynecol Pathol; 2024 Jan; 43(1):78-89. PubMed ID: 37255476
[TBL] [Abstract] [Full Text] [Related]
6. ovarian Granulosa Cell Tumor Initially Presenting as a Giant Liver Mass Radiologically Mimicking Primary Cystic Cholangiocarcinoma.
Qian X; Cong Z; Lai J
In Vivo; 2023; 37(2):734-737. PubMed ID: 36881092
[TBL] [Abstract] [Full Text] [Related]
7. Lymphocyte activation gene (LAG)-3 is a potential immunotherapeutic target for microsatellite stable, programmed death-ligand 1 (PD-L1)-positive endometrioid endometrial cancer.
Hong JH; Cho HW; Ouh YT; Lee JK; Chun Y
J Gynecol Oncol; 2023 Mar; 34(2):e18. PubMed ID: 36509464
[TBL] [Abstract] [Full Text] [Related]
8. Cooperative effects of oocytes and estrogen on the forkhead box L2 expression in mural granulosa cells in mice.
Ito H; Emori C; Kobayashi M; Maruyama N; Fujii W; Naito K; Sugiura K
Sci Rep; 2022 Nov; 12(1):20158. PubMed ID: 36424497
[TBL] [Abstract] [Full Text] [Related]
9. Expression and T cell regulatory action of the PD-1 immune checkpoint in the ovary and fallopian tube.
Johnson J; Kim SY; Sam PK; Asokan R; Cari EL; Bales ES; Luu TH; Perez L; Kallen AN; Nel-Themaat L; Polotsky AJ; Post MD; Orlicky DJ; Jordan KR; Bitler BG
Am J Reprod Immunol; 2023 Mar; 89(3):e13649. PubMed ID: 36394352
[TBL] [Abstract] [Full Text] [Related]
10. The Tumor Microenvironment of Clear-Cell ovarian cancer.
Devlin MJ; Miller R; Laforets F; Kotantaki P; Garsed DW; Kristeleit R; Bowtell DD; McDermott J; Maniati E; Balkwill FR
Cancer Immunol Res; 2022 Nov; 10(11):1326-1339. PubMed ID: 36095166
[TBL] [Abstract] [Full Text] [Related]
11. Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in ovarian cancer Patients.
Pawłowska A; Kwiatkowska A; Suszczyk D; Chudzik A; Tarkowski R; Barczyński B; Kotarski J; Wertel I
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768993
[TBL] [Abstract] [Full Text] [Related]
12. Construction of an Immune Cell Infiltration Score to Evaluate the Prognosis and Therapeutic Efficacy of ovarian cancer Patients.
Liu J; Wang Y; Yuan S; Wei J; Bai J
Front Immunol; 2021; 12():751594. PubMed ID: 34745124
[TBL] [Abstract] [Full Text] [Related]
13. Progress in the management of ovarian granulosa cell tumor: A review.
Li J; Chu R; Chen Z; Meng J; Yao S; Song K; Kong B
Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1771-1778. PubMed ID: 34027996
[TBL] [Abstract] [Full Text] [Related]
14. Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in ovarian cancer.
Miao YR; Thakkar KN; Qian J; Kariolis MS; Huang W; Nandagopal S; Yang TTC; Diep AN; Cherf GM; Xu Y; Moon EJ; Xiao Y; Alemany H; Li T; Yu W; Wei B; Rankin EB; Giaccia AJ
Clin Cancer Res; 2021 Aug; 27(15):4435-4448. PubMed ID: 34011561
[TBL] [Abstract] [Full Text] [Related]
15. DSCMF: prediction of LncRNA-disease associations based on dual sparse collaborative matrix factorization.
Liu JX; Gao MM; Cui Z; Gao YL; Li F
BMC Bioinformatics; 2021 May; 22(Suppl 3):241. PubMed ID: 33980147
[TBL] [Abstract] [Full Text] [Related]
16. Triazole-Based Half-Sandwich Ruthenium(II) Compounds: From
Lenis-Rojas OA; Cabral R; Carvalho B; Friães S; Roma-Rodrigues C; Fernández JAA; Vila SF; Sanchez L; Gomes CSB; Fernandes AR; Royo B
Inorg Chem; 2021 Jun; 60(11):8011-8026. PubMed ID: 33973771
[TBL] [Abstract] [Full Text] [Related]
17. Gold(III) complexes with thiosemicarbazonate ligands as potential anticancer agents: Cytotoxicity and interactions with biomolecular targets.
Possato B; Dalmolin LF; Pereira LM; Alves JQ; Silva RTC; Gelamo RV; Yatsuda AP; Lopez RFV; de Albuquerque S; Leite NB; Maia PIDS
Eur J Pharm Sci; 2021 Jul; 162():105834. PubMed ID: 33826936
[TBL] [Abstract] [Full Text] [Related]
18. Copper(ii) complexes with tridentate halogen-substituted Schiff base ligands: synthesis, crystal structures and investigating the effect of halogenation, leaving groups and ligand flexibility on antiproliferative activities.
Kordestani N; Amiri Rudbari H; Fernandes AR; Raposo LR; Luz A; Baptista PV; Bruno G; Scopelliti R; Fateminia Z; Micale N; Tumanov N; Wouters J; Abbasi Kajani A; Bordbar AK
Dalton Trans; 2021 Mar; 50(11):3990-4007. PubMed ID: 33650599
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic and Clinical Value of Interleukin 6 and CD45
Wertel I; Suszczyk D; Pawłowska A; Bilska M; Chudzik A; Skiba W; Paduch R; Kotarski J
J Immunol Res; 2020; 2020():1715064. PubMed ID: 33062717
[TBL] [Abstract] [Full Text] [Related]
20. Further Approaches in the Design of Antitumor Agents with Response to Cell Resistance: Looking toward Aza Crown Ether-dtc Complexes.
Arenaza-Corona A; Couce-Fortúnez MD; de Blas A; Morales-Morales D; Santillan R; Höpfl H; Rodríguez-Blas T; Barba V
Inorg Chem; 2020 Oct; 59(20):15120-15134. PubMed ID: 33000942
[TBL] [Abstract] [Full Text] [Related]
[Next]
